文献速递神经肿瘤

长期DMPA使用相关的颅内脑膜瘤特征:系统综述与病例系列

Pattern of Intracranial Meningiomas Associated With Prolonged DMPA Use: Systematic Review of Synthetic Progestins and Case Series of DMPA-Associated Intracranial Meningiomas.
PubMed 文献 · Neurosurgery · 2026-04-21

本研究通过系统综述和单中心回顾性病例对照研究,描述长期使用长效醋酸甲羟孕酮(DMPA)相关的颅内脑膜瘤的临床、影像和病理特征。结果显示DMPA相关脑膜瘤多为多发、骨侵袭性、孕激素受体(PR)阳性,且常位于海绵窦和蝶骨平台。对于无症状病灶,可考虑停药观察后再决定手术。

要点

  • 长期DMPA使用与多发、骨侵袭、PR阳性脑膜瘤相关。
  • DMPA相关脑膜瘤骨侵袭率50.0%,对照组17.5%。
  • 无症状病灶可考虑停药观察,但需前瞻性验证。

核心结论

  • 长期DMPA使用与一种独特的多发、骨侵袭、PR阳性脑膜瘤模式相关。

研究设计与样本

  • 基于PRISMA的系统综述联合单中心回顾性病例对照研究(2014-2024)。
  • 纳入连续使用DMPA≥2年且组织学确诊颅内脑膜瘤的女性,对照为年龄和性别匹配的无DMPA暴露手术脑膜瘤病例。

主要发现

  • 系统综述识别32项研究,显示高剂量孕激素与脑膜瘤风险显著增加相关,停药后肿瘤可退缩。
  • 机构分析纳入95例患者:38例DMPA暴露者(中位年龄44.6岁;中位暴露129个月)共85个肿瘤,57例对照。
  • DMPA相关脑膜瘤骨侵袭率50.0% vs 17.5%(P < .001),海绵窦位置39.5% vs 15.8%(P = .01),蝶骨平台位置21.1% vs 7.0%(P = .04),每患者肿瘤数更高(P < .001)。
  • PR表达在DMPA肿瘤中普遍阳性(100% vs 61.8%;P < .001)。
  • 多变量分析中,肿瘤多发(OR 12.2;P = .0057)和PR阳性(OR 69.6;P < .001)独立预测DMPA暴露。

关键数值与推荐

  • DMPA暴露定义为连续使用≥2年。
  • 骨侵袭率50.0% vs 17.5%(P < .001)。
  • 海绵窦位置39.5% vs 15.8%(P = .01)。
  • 蝶骨平台位置21.1% vs 7.0%(P = .04)。
  • PR阳性率100% vs 61.8%(P < .001)。

临床怎么用

  • 对于长期DMPA使用者的无症状脑膜瘤,可考虑停药观察后再决定手术干预。

局限性

  • 基于其他孕激素的既有模式外推,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In recent years, reports have demonstrated a unique set of features shared among meningioma patients with a history of prolonged progestin use. This has not yet been described for patients with prolonged use of depot medroxyprogesterone acetate (DMPA), commonly used in the United States. To characterize the clinical, radiological, and pathological features of DMPA-associated meningiomas and compare them with a matched, nonexposed control cohort. METHODS: A preferred reporting items for systematic reviews and meta-analysis-based systematic review of progestin-associated meningiomas was performed followed by a single-center retrospective case-control study (2014-2024). Women with ≥2 years of uninterrupted DMPA use and histologically confirmed intracranial meningioma were included. Age-matched and sex-matched surgical meningioma cases without DMPA exposure served as controls. Outcomes included tumor multiplicity, location, osseous invasion, progesterone-receptor (PR) status, and histopathology. Multivariable logistic regression assessed independent associations with DMPA use. RESULTS: The systematic review identified 32 studies showing that high-dose progestins were associated with significant increased meningioma risk and reported tumor regression after drug withdrawal. Institutional analysis included 95 patients: 38 DMPA-exposed (median age 44.6 years; median exposure 129 months) harboring 85 tumors and 57 controls. DMPA-associated meningiomas showed markedly higher rate of osseous invasion (50.0% vs 17.5%; P < .001), were located in the cavernous sinus (39.5% vs 15.8%, P = .01) and planum sphenoidale (21.1% vs 7.0%, P = .04), and higher number of meningiomas per patient (P < .001). PR expression was universal in DMPA tumors (100% vs 61.8%; P < .001). On multivariable analysis, tumor multiplicity (odds ratio 12.2; P = .0057) and PR positivity (odds ratio 69.6; P < .001) independently predicted DMPA exposure. CONCLUSION: Long-term DMPA use is associated with a distinct pattern of multiple, bone-invasive, PR-positive meningiomas. Based on established patterns with other progestins, drug discontinuation and observation before surgical intervention should be considered for asymptomatic lesions, although prospective validation is warranted.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Abou-Al-Shaar H, Wrigley R, Passeri T, et al. Pattern of Intracranial Meningiomas Associated With Prolonged DMPA Use: Systematic Review of Synthetic Progestins and Case Series of DMPA-Associated Intracranial Meningiomas. Neurosurgery. 2026. PMID: 42012174. doi:10.1227/neu.0000000000004031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。